MannKind/MNKD

2.18%
-
1D1W1MYTD1YMAX

About MannKind

MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Ticker

MNKD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Michael Castagna

Employees

414

Headquarters

Danbury, United States

MannKind Metrics

BasicAdvanced
US$1.2B
Market cap
195.90
P/E ratio
US$0.02
EPS
1.26
Beta
-
Dividend rate
US$1.2B
1.26255
US$5.75
US$3.17
2.9M
3.835
3.57
1.5%
2.18%
2.84%
195.903
5.565
402.813
74.92%
108.51%
45.09%

What the Analysts think about MannKind

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
50.96% upside
High US$10.00
Low US$5.00
US$4.69
Current price
US$7.08
Average price target

MannKind Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
16.01% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
US$66M
13.36%
Net income
US$11M
657.14%
Profit margin
16.01%
569.87%

MannKind Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 53.85%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-US$0.02
US$0.01
-
US$0.04
-
Expected
-US$0.04
-US$0.02
US$0.00
US$0.03
US$0.01
Surprise
-47.37%
-160.61%
-
53.85%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for MannKind stock?

MannKind (MNKD) has a market cap of $1.2B as of May 20, 2024.

What is the P/E ratio for MannKind stock?

The price to earnings (P/E) ratio for MannKind (MNKD) stock is 195.9 as of May 20, 2024.

Does MannKind stock pay dividends?

No, MannKind (MNKD) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next MannKind dividend payment date?

MannKind (MNKD) stock does not pay dividends to its shareholders.

What is the beta indicator for MannKind?

MannKind (MNKD) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the MannKind stock price target?

The target price for MannKind (MNKD) stock is $7.08, which is 50.64% above the current price of $4.7. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell MannKind stock

Buy or sell MannKind stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing